{"nctId":"NCT01467466","briefTitle":"Prevention of Serious Adverse Events Following Angiography","startDateStruct":{"date":"2013-10-07","type":"ACTUAL"},"conditions":["Acute Renal Failure","Kidney Disease","Coronary Artery Disease"],"count":5177,"armGroups":[{"label":"Saline & oral placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IV isotonic saline","Drug: Placebo"]},{"label":"Saline & oral N-acetylcysteine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IV isotonic saline","Drug: N-acetylcysteine"]},{"label":"Bicarbonate & oral placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IV isotonic bicarbonate","Drug: Placebo"]},{"label":"Bicarbonate & oral N-acetylcysteine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IV isotonic bicarbonate","Drug: N-acetylcysteine"]}],"interventions":[{"name":"IV isotonic saline","otherNames":[]},{"name":"IV isotonic bicarbonate","otherNames":[]},{"name":"N-acetylcysteine","otherNames":["NAC"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Planned elective or urgent coronary or non-coronary angiography with iodinated contrast media in which it is anticipated that there will be an interval of 3 hours between the identification of the indication for angiography and the time of the planned procedure.\n* Pre-angiography eGFR \\<60 ml/min/1.73 m2 with diabetes mellitus or pre-angiography eGFR \\<45 ml/min/1.73 m2 with or without diabetes mellitus\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Stage 5 chronic kidney disease (CKD) (eGFR \\<15 mL/min/1.73 m2)\n* Currently receiving hemodialysis, peritoneal dialysis, continuous renal replacement therapy, or sustained low efficiency dialysis (SLED)\n* Unstable baseline serum creatinine (SCr) (if known) at the time of angiography defined by an increase in SCr of 25% over the 3 days prior to angiography\n* Decompensated heart failure requiring any of the following therapies at the time of angiography:\n\n  * IV milrinone, amrinone, dobutamine, or nesiritide\n  * Isolated ultrafiltration therapy\n  * Intra-aortic balloon pump\n* Emergent angiography procedures defined as an anticipated duration of \\<3 hours between the identification of the indication for angiography and the time of the planned procedure.\n* Receipt of intravascular iodinated contrast within the 5 days preceding angiography\n* Receipt of oral or IV NAC within the 48 hours preceding angiography\n* Known allergy to N-acetylcysteine (NAC)\n* Known anaphylactic allergy to iodinated contrast media\n* Prisoner\n* Age \\<18 years\n* Pregnancy\n* Ongoing participation in an unapproved concurrent interventional study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Intravenous Sodium Bicarbonate With Intravenous Sodium Chloride.","description":"Death will be based on medical record and/or vital status registry documentation Need for acute dialysis will be defined as the initiation of any modality of renal replacement (intermittent hemodialysis, peritoneal dialysis, continuous renal replacement therapy, or sustained low-efficiency dialysis) Persistent decline in kidney function will be defined as an increase in serum creatinine of at least 50% from the baseline value collected pre-angiography to the measurement taken 90 days following the angiography.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"116","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo.","description":"Death will be based on medical record and/or vital status registry documentation Need for acute dialysis will be defined as the initiation of any modality of renal replacement (intermittent hemodialysis, peritoneal dialysis, continuous renal replacement therapy, or sustained low-efficiency dialysis) Persistent decline in kidney function will be defined as an increase in serum creatinine of at least 50% from the baseline value collected pre-angiography to the measurement taken 90 days following the angiography.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":941,"n":1300},"commonTop":["Dyspepsia","Nausea","Diarrhoea","Vomiting","Dizziness"]}}}